来曲唑用于多囊卵巢综合征女性冻融胚胎移植:一项随机对照试验
该随机对照试验纳入420例多囊卵巢综合征(PCOS)行冻融胚胎移植(FET)的女性,比较来曲唑诱导排卵与人工周期准备内膜的活产率。来曲唑组与人工周期组活产率无差异(42.4% vs 42.9%,P>.99),来曲唑组妊娠期糖尿病(GDM)发生率更高(14.6% vs 5.6%,P=.050),人工周期组单胎出生体重更高(3,108±56 g vs 3,301±58 g,P=.018)。
要点
- PCOS患者FET周期中来曲唑与人工周期准备内膜的活产率无差异(42.4% vs 42.9%,P>.99)。
- 来曲唑组GDM发生率显著高于人工周期组(14.6% vs 5.6%,P=.050)。
- 人工周期组单胎出生体重显著高于来曲唑组(3,301±58 g vs 3,108±56 g,P=.018)。
核心结论
- PCOS患者FET周期中来曲唑诱导排卵与人工周期准备内膜的妊娠结局无差异。
- 来曲唑组GDM风险更高,人工周期组单胎出生体重更低。
研究设计与样本
- 随机对照试验,2018年至2021年纳入420例PCOS行FET的女性,来曲唑组210例,人工周期组210例。
- 主要结局为每移植周期活产率;假设α=0.05、80%把握度,每组需186例以检出15%活产率差异,按10%脱落率每组至少随机205例。
主要发现
- 活产率来曲唑组42.4% vs 人工周期组42.9%(P>.99)。
- 临床妊娠率来曲唑组51.4% vs 人工周期组56.2%(P=.378)。
- 种植率来曲唑组51.8% vs 人工周期组55.8%(P=.401)。
- 流产率来曲唑组8.6% vs 人工周期组11.0%(P=.511)。
- 单胎出生体重人工周期组3,301±58 g vs 来曲唑组3,108±56 g(P=.018);GDM发生率来曲唑组14.6% vs 人工周期组5.6%(P=.050)。
关键数值与推荐
- 主要结局活产率两组无差异(42.4% vs 42.9%,P>.99)。
- GDM发生率来曲唑组14.6% vs 人工周期组5.6%(P=.050)。
- 单胎出生体重人工周期组3,301±58 g vs 来曲唑组3,108±56 g(P=.018)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare live-birth rates between letrozole application and artificial cycle for endometrium preparation during frozen embryo transfer (FET) cycle among women with polycystic ovarian syndrome (PCOS). METHODS: A randomized controlled trial was conducted. Women with PCOS were randomized to letrozole application for ovulation induction compared with artificial cycle for endometrial preparation during FET. The primary outcome was live-birth rate per embryo transfer. Secondary outcomes included pregnancy-related outcomes, perinatal outcomes, and maternal complication rates. Assuming α=0.05 and 80% power, 186 patients per group were required to demonstrate a difference of 15% in live-birth rate: 205 patients (at least) per group were randomized to allow for a 10% dropout rate. RESULTS: Four hundred twenty patients were enrolled from 2018 to 2021. Two hundred ten patients were assigned to the letrozole application group, and 210 were assigned to the artificial cycle group. There was no difference in the live-birth rate (42.4% vs 42.9%, P =>.99). There was no difference in secondary outcomes, including clinical pregnancy rate (51.4% vs 56.2%, P =.378), implantation rate (51.8% vs 55.8%, P =.401), and miscarriage rate (8.6% vs 11.0%, P =.511). For perinatal outcomes, singleton birth weight was significantly higher in the artificial cycle group (3,108±56 g vs 3,301±58, P =.018), and the incidence of gestational diabetes mellitus (GDM) was significantly higher in letrozole application group (14.6% vs 5.6%, P =.050). The other outcome was no difference in maternal complications. CONCLUSION: There was no difference in pregnancy outcomes between letrozole application compared with artificial cycle for endometrial preparation in women with PCOS who underwent FET. The risk of GDM was higher in the letrozole application group, and the singleton birth weight was lower in the artificial cycle group. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800014746.
引用
- Yuan Y, Chang Q, Wen Y, et al. Letrozole During Frozen Embryo Transfer in Women With Polycystic Ovarian Syndrome: A Randomized Controlled Trial. Obstet Gynecol. 2023. PMID: 37708500. doi:10.1097/AOG.0000000000005367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。